期刊文献+

酒石酸托特罗定治疗膀胱过度活动症的疗效观察 被引量:7

下载PDF
导出
摘要 目的观察酒石酸托特罗定治疗膀胱过度活动症(OAB)的疗效和不良反应。方法对128例符合诊断标准的OAB患者口服酒石酸托特罗定片,2 mg/次,2次/d,疗程4周,治疗前后分别行OAB症状评分(OABSS),观察患者日间排尿次数、夜尿次数、平均24 h尿急次数、平均尿失禁次数的变化和不良反应情况。结果治愈80例(62.5%),显效37例(28.9%),无效11例(8.6%)。用药后日间排尿次数、夜尿次数、平均24 h尿急次数、平均尿失禁次数及OABSS总评分较用药前均明显减少,用药前后比较差异有统计学意义。发生不良反应18例(14%),均为轻度口干、眼干、便秘等,无严重不良反应。结论酒石酸托特罗定能有效减轻OAB患者尿急、尿频、夜尿、尿失禁等症状,疗效确切,不良反应发生率低,安全有效。
作者 张军杰
出处 《河南外科学杂志》 2012年第2期53-54,共2页 Henan Journal of Surgery
  • 相关文献

参考文献7

  • 1Taylor, Pall. Pharmacologic Management of Overactive Bladder [ J ]. Journal of Wound, Ostomy and Continence Nursing ,2005, 32:1 -24.
  • 2Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndrome -overactive bladder symptom score [ J ]. Urology,2006,68:318 - 323.
  • 3许克新,汪磊,王晓峰,那彦群,叶章群,黄翼然,宋波,孔垂泽.膀胱过度活动症症状评分表对中国OAB患者结果评估的重复信度及与其他症状评分工具间相关性的研究[J].中华泌尿外科杂志,2010,31(11):727-731. 被引量:103
  • 4Chapple CR, Van Kerrebroeck PE, Junemann KP, et al. Com- parison of fesoterodine and tolterodine in patients with overac- tive bladder[ J ]. BJU Int,2008,102 : 1 128 - 1 132.
  • 5Hills CJ, Winter SA, Balfour JA. Tolterrodine. Durg, 1998,55 : 822.
  • 6Kanofsky JK, Nitti VW. Tolterrodine for treatment of overactive bladder[ J ]. Urol Clin North Am,2006,33:447 - 453.
  • 7Lam S, Hilas O. Pharamacologic management of overactive blad- der[ J ]. Clin Interv Aging,2007,2 : 337 - 345.

共引文献102

同被引文献48

  • 1Golsong J.Overactive bladder[J].MMW Fortschr Med,2013,155(6):44.
  • 2De G,Yang H,Runken MC,et al.Impact of mirabegron treatment and symptom severity on work productivity and activity impairment in patients with overactive bladder[J].Value Health,2013,16(3):A183-A185.
  • 3Orasanu B,Mahajan ST.The use of botulinum toxin for the treatment of overactive bladder syndrome[J].Indian J Urol,2013,29(1):2-11.
  • 4Cornu JN,Haab F.Pharmacological treatment of idiopathic overactive bladder:a literature review[J].Prog Urol,2013,23(4):227-236.
  • 5Cornu JN.Actual treatment of overactive bladder and urge urinary incontinence[J].Minerva Urol Nefrol,2013,65(1):21-35.
  • 6Kul'chavenia EV,Brizhatiuk EV,Breusov AA.Overactive bladder as a mask of chronic prostatitis[J].Urologiia,2012,(6):43-44,46.
  • 7Nowakowski (L),Kulik-Rechberger B,Wróbel A,et al.Overactive bladder:a new insight into the pathogenesis of its idiopathic form[J].Ginekol Pol,2012,83(11):844-848.
  • 8Shahani R, Streutker C, Dickson B, et al. Ketamine- associated ulcerative cystitis: a new clinical entity[J]. Urology, 2007, 69(5): 810-812.
  • 9Lee SH, Lee JY. Churrent role of treat in men with lower urinary tract symptoms combined with overactive bladder [J]. Prostate Int, 2014, 2(2): 43-49.
  • 10Chess-Williams R. Muscarinic receptors of the urinary bladder: de- trusor, urothelial and prejunctional [J]. Auton Autacoid Pharmacol, 2002, 22(3): 133-145.

引证文献7

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部